Q4 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Equities research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share (EPS) estimates for shares of Illumina in a report released on Monday, November 4th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings of $0.89 per share for the quarter, down from their prior forecast of $0.93. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s Q1 2025 earnings at $0.84 EPS, Q2 2025 earnings at $0.97 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.14 EPS and FY2026 earnings at $4.92 EPS.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 earnings per share.

Several other research firms also recently weighed in on ILMN. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Wednesday, August 28th. Barclays upped their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, Scotiabank cut their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $162.18.

Illumina Stock Up 2.2 %

ILMN stock opened at $155.15 on Thursday. The stock has a fifty day moving average of $137.27 and a 200-day moving average of $123.12. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $156.66. The company has a market capitalization of $24.72 billion, a price-to-earnings ratio of -15.58 and a beta of 1.13. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11.

Hedge Funds Weigh In On Illumina

Hedge funds have recently made changes to their positions in the business. Prospera Financial Services Inc boosted its stake in shares of Illumina by 2.8% during the 3rd quarter. Prospera Financial Services Inc now owns 28,808 shares of the life sciences company’s stock valued at $3,757,000 after purchasing an additional 783 shares in the last quarter. Whalen Wealth Management Inc. purchased a new position in shares of Illumina during the 3rd quarter worth approximately $480,000. Caprock Group LLC raised its position in shares of Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares in the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in shares of Illumina in the 3rd quarter valued at approximately $224,000. Finally, LMR Partners LLP purchased a new position in shares of Illumina in the 3rd quarter valued at approximately $2,776,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.